Cipla shares dropped 5% after reporting a 57% year-on-year decline in net profit to Rs 676 crore, impacted by a fall in gRevlimid sales. Re...

Cipla aims for $1 billion in US sales by FY27, offsetting Revlimid's patent expiry with new launches, particularly in respiratory generics ...

Indian pharma and healthcare companies anticipate improved revenue and profit in the June 2025 quarter, fueled by domestic market growth. H...

Cipla's Q3FY25 revenue is expected to grow 3.1-7%, with profit estimates ranging from a 2.2% decline to 14% growth. Brokerages have differi...

The steady generic pricing is a tailwind and execution of key launches like gAbraxane for Cipla will determine the path of US sales in 2025.

Cipla is set to report a 3-6% revenue growth for the September quarter, as forecasted by four brokerages. The earnings for Q2FY25 will be a...

Cipla reported Q1FY25 net profit expected between Rs 1,061-1,135 crore, with YoY growth of 6.5%-14%. Revenue estimated at Rs 6,749-6,879 cr...

Q4 results today: Several other companies scheduled to release their financial results include Cholamandalam Finance, Eicher Motors, Finole...

Cipla Q4 Results Preview: As per the combined projections of four brokerages, there's a possibility of the net profit for the fourth quarte...

Alembic Pharma Q4 Results: Indian generic drugmaker Alembic Pharma reported a 17% rise in fourth-quarter profit on Thursday, driven by stro...

Cipla could deliver healthy growth of 5% in the Indian business in the second quarter, but the US business is likely to witness pressure on...

Global investment bank Citi maintained a buy rating on Cipla and Morgan Stanley maintained an overweight rating on Axis Bank. Motilal Oswal...

EBITDA margin improved by 176 bps YoY to 24.2% despite soft Revlimid sales, mainly driven by an improvement in the mix. The net profit grew...

Cipla reported a multi-quarter high of $179 million in revenue and 25% YoY growth led by the successful launch of a generic version of the ...

Revlimid is a top-selling cancer drug from Bristol Myers Squibb. Its generic form, called lenalidomide, is seen as Dr Reddy's most anticipa...

Cipla Ltd., incorporated in the year 1935, is a Large Cap company (having a market cap of Rs 81586.39 Crore) operating in Pharmaceuticals s...

Cipla reported an FCF of around Rs 3,400 crore in 2019-20 and is expected to report bigger numbers in the coming years due to increased gro...